PMID- 19557118
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110426
LR  - 20211020
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 5
DP  - 2009
TI  - Update on the use of memantine in Alzheimer's disease.
PG  - 237-47
AB  - Memantine is a low to moderate affinity N-methyl-D-aspartate receptor (NMDAR) 
      antagonist. The effects of memantine in Alzheimer's disease (AD) have been 
      studied in 7 randomized controlled trials in many post-hoc analyses. Three out of 
      four RCTs in patients with moderate to severe AD (Mini Mental State Examination 
      [MMSE] <14) showed a statistically significant but clinically small positive 
      effect of memantine on cognition, global functioning, activities of daily living 
      (ADL) and neuropsychiatric symptoms. No effects on these outcome measures could 
      be found in the three RCTs studying patients with mild to moderate AD (MMSE 
      14-24). Two of these studies evaluated the effect of addition of memantine to 
      donepezil. Only the study in patients with mild to moderate AD showed a positive 
      effect of addition of memantine on cognition, ADL, global functioning and 
      neuropsychiatric functioning. Cost-effectiveness of memantine therapy remains 
      controversial. Post-hoc analyses and observational studies suggest some effects 
      on agitation/aggression, delusions or hallucinations. Side effects of memantine 
      are usually mild and seem to be comparable with placebo. In this review, an 
      oversight of pharmacodynamics and pharmacokinetics of memantine is presented. 
      Also, published data concerning efficacy and safety in patients with AD are 
      presented.
FAU - van Marum, Robert J
AU  - van Marum RJ
AD  - Geriatric Department, University Medical Center Utrecht, Utrecht, The 
      Netherlands. r.j.vanmarum@umcutrecht.nl
LA  - eng
PT  - Journal Article
DEP - 20090520
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC2695219
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - dementia
OT  - drug therapy
OT  - memantine
EDAT- 2009/06/27 09:00
MHDA- 2009/06/27 09:01
PMCR- 2009/01/01
CRDT- 2009/06/27 09:00
PHST- 2009/06/27 09:00 [entrez]
PHST- 2009/06/27 09:00 [pubmed]
PHST- 2009/06/27 09:01 [medline]
PHST- 2009/01/01 00:00 [pmc-release]
AID - ndt-5-237 [pii]
AID - 10.2147/ndt.s4048 [doi]
PST - ppublish
SO  - Neuropsychiatr Dis Treat. 2009;5:237-47. doi: 10.2147/ndt.s4048. Epub 2009 May 
      20.